Figma Shares Indicated To Open $105/$110
Kathleen Skarvan, a director at Electromed, Inc. (NYSE:ELMD), recently reported significant stock transactions involving the company’s common stock. The transactions come as the stock has shown remarkable strength, posting a 115% gain over the past year according to InvestingPro data. On February 14, 2025, Skarvan exercised options to acquire 40,000 shares at a price of $1.80 per share. Subsequently, she sold a total of 32,629 shares on the same day, with sale prices ranging from $31.70 to $33.15. The sales continued on February 18, 2025, with an additional 43,954 shares sold at prices between $29.14 and $29.83. The total value of these sales amounted to approximately $2.33 million. The stock has recently experienced an 11% decline over the past week, though it maintains a strong financial position with a current ratio of 5.1 and minimal debt.
After these transactions, Skarvan’s direct ownership stands at 32,622 shares, with no shares remaining in trust. These transactions were part of Skarvan’s broader financial and retirement planning strategy. For deeper insights into insider trading patterns and comprehensive financial analysis, including 10 additional ProTips, explore the full company profile on InvestingPro.
In other recent news, Electromed Inc . reported its financial results for the second quarter of fiscal year 2025, highlighting a strong performance with a record net income of $2 million, or $0.22 per diluted share, which surpassed earnings forecasts. The company achieved revenue of $16.3 million, reflecting an 18.7% year-over-year growth, driven by robust demand across its product lines. Electromed’s earnings per share exceeded the forecast of $0.19, marking a surprise of approximately 15.8%, while revenue surpassed the anticipated $15.3 million. Analysts from Lake Street Capital Markets noted the company’s consistent performance and the effective management of its sales team. Electromed continues to focus on expanding its sales infrastructure and enhancing operational efficiencies, as indicated in their earnings call. The company also highlighted its strategic investments in the SmartVest Clearway (NYSE:CWEN) technology and its direct patient model, which have contributed to its sustained growth. Additionally, Electromed is monitoring potential complementary drug treatments for bronchiectasis patients, which could further strengthen its market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.